DAPA-CKD: SGLT2 Inhibitors ' The Beta-Blockers for the Kidneys ' DAPA-CKD: SGLT2 Inhibitors ' The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Nephrology Commentary Source Type: news
More News: Beta-Blockers | Dapagliflozin | Forxiga | Intensive Care | SGLT2 Inhibitors | Urology & Nephrology